

CITATION REPORT

List of articles citing

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

DOI: 10.1016/j.tmaid.2020.101738

Travel Medicine and Infectious Disease, 2020, 35, 101738.

Source: <https://exaly.com/paper-pdf/76587826/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
344	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
343	Methylene blue inhibits replication of SARS-CoV-2 in vitro. 2020 , 56, 106202		29
342	Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19. 2020 , 13, 3689-3694		6
341	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <i>Travel Medicine and Infectious Disease</i> , 2020 , 37, 101873	8.4	38
340	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". 2020 , 14, 1673-1680		31
339	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672		31
338	Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence. <i>Travel Medicine and Infectious Disease</i> , 2020 , 38, 101886 ^{8.4}		
337	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519		16
336	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541		4
335	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. 2020 , 383, 2030-2040		628
334	Nullane salus extra ecclesiam. 2020 , 37, 100714		2
333	Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. <i>Travel Medicine and Infectious Disease</i> , 2020 , 37, 101826	8.4	2
332	Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India. 2020 , 14, 1777-1781		3
331	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. 2020 , 56, 106143		51
330	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. 2020 , 38, 100776		20
329	Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients. <i>Travel Medicine and Infectious Disease</i> , 2020 , 38, 101881	8.4	3
328	Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. 2020 , 13, 1183-1190		5

327	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". 2020 , 189, 1442-1443	5
326	Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of arteminol for COVID-19. 2021 , 39, 6184-6194	29
325	Treatment of COVID-19 - Evidence-Based or Personalized Medicine?. 2020 ,	3
324	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190	44
323	Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis. 2020 , 147, 104390	41
322	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374	9
321	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. <i>Pathogens</i> , 2020 , 9,	4.5 23
320	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,	2
319	COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies. 2020 , 7, 573188	15
318	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. 2020 , 29, 100645	34
317	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. 2021 , 199, 3642-3646	28
316	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. 2020 , 10,	16
315	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). 2020 , 4, 121-131	
314	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. 2020 , 56, 106224	5
313	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,	4
312	Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020. 2020 , 56, 106219	28
311	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 2020 , 173, 623-631	298
310	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. <i>Frontiers in Pharmacology</i> , 2020 , 11, 559996	5.6 1

309	Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?. 2020 , 189, 1227-1229	5
308	Risch Responds to "How to Consider Low Reported Death Rates in COVID-19". 2020 , 189, 1230-1231	2
307	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
306	THE AUTHOR REPLIES. 2020 , 189, 1444-1449	3
305	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159	22
304	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,	27
303	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18
302	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
301	Management of Severe COVID-19 in Pregnancy. 2020 , 2020, 8852816	4
300	[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. 2020 , 46 Suppl 1, 20-27	0
299	The "Infodemic" of COVID-19. 2020 , 72, 1806-1808	18
298	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. 2020 , 56, 106129	7
297	Early Treatment of COVID-19 Disease: A Missed Opportunity. 2020 , 9, 715-720	13
296	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
295	Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". <i>Travel Medicine and Infectious Disease</i> , 2020 , 37, 101861	8.4 5
294	Current Options in the Treatment of COVID-19: A Review. 2020 , 13, 1999-2010	5
293	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. 2020 , 11, 570927	21
292	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. 2020 , 7, 562142	11

291	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. 2020 , 56, 106214	53
290	Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. 2020 , 31, 100627	17
289	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
288	Observational study of azithromycin in hospitalized patients with COVID-19. 2020 , 15, e0238681	14
287	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. 2020 , 396, 959-967	183
286	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. 2020 , 1, 965-975	58
285	Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis. 2020 , 21, e13089	34
284	Knowledge, Attitude, and Practices of Healthcare Professionals on COVID-19 and Risk Assessment to Prevent the Epidemic Spread: A Multicenter Cross-Sectional Study from Punjab, Pakistan. 2020 , 17,	18
283	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. 2020 , 25,	4
282	C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis. 2020 , 5, 14	3
281	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2
280	Is there any potential management against COVID-19? A systematic review and meta-analysis. 2020 , 28, 765-777	9
279	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
278	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41
277	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. 2020 , 33, 177-189	0
276	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. 2020 , 17,	6
275	Mortality & Hydroxychloroquine; Politics & Pandemic: Strange liaisons lead to strange correlations: Mortality & Hydroxychloroquine; Politiques & Pandémie: D'étranges liaisons impliquent d'étranges corrélations. 2020 , 38, 100749	0
274	A Note From the Editors. 2020 , 189, 1215-1217	1

273	Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic. 2020 , 21, 922-923		2
272	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747		11
271	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. 2020 , 25,		42
270	Lack of efficacy of hydroxychloroquine in covid-19. 2020 , 369, m2018		10
269	An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. <i>Travel Medicine and Infectious Disease</i> , 2020 , 37, 101755	8.4	104
268	The endosomal lipid bis(monoacylglycerol) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246		12
267	Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.). 2020 , 14, 729		2
266	"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.". 2020 , 14, 589-596		78
265	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. 2020 , 9, 435-449		35
264	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). 2020 , 40, 591-601		55
263	Covid-19: a comprehensive review of a formidable foe and the road ahead. 2020 , 14, 869-879		9
262	Possible therapeutic agents for COVID-19: a comprehensive review. 2020 , 18, 1005-1020		13
261	Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center. <i>Travel Medicine and Infectious Disease</i> , 2020 , 36, 101788	8.4	7
260	Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?. <i>Travel Medicine and Infectious Disease</i> , 2020 , 35, 101764	8.4	3
259	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829		3
258	COVID-19 research: an opinion piece. 2020 , 21, 536-540		3
257	Hydroxychloroquine for COVID-19: Myths vs facts. 2020 , 33, e13857		4
256	Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. 2020 , 38, 100709		48

255	Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. 2020 , 33, e13785		9
254	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. 2020 , 38, 100710		6
253	Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. 2020 , 228, 971-975		59
252	Chloroquine and COVID-19: A western medical and scientific drift?. 2020 , 78, 4-5		3
251	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020 , 97, 396-403	10.5	330
250	Hydroxychloroquine and COVID-19 - A narrative review. 2020 , 67, S147-S154		5
249	No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". <i>Travel Medicine and Infectious Disease</i> , 2020 , 36, 101819	8.4	2
248	Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. 2020 , 75, 335-342		5
247	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. 2020 , 18, 1119-1133		16
246	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606		17
245	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2020 , 36, 101791	8.4	162
244	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. 2020 , 56, 106078		29
243	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. 2020 , 1, 100016		79
242	Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. 2020 , 92, 776-785		127
241	Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. 2021 , 53, 141-170		15
240	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59		1
239	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717		14
238	Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. 2021 , 90, 107157		18

237	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. 2021 , 73, 36-47	34
236	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. 2021 , 134, 16-22	55
235	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. 2021 , 73, 48-52	5
234	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121	8
233	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. 2021 , 538, 156-162	4
232	High-speed large-scale automated isolation of SARS-CoV-2 from clinical samples using miniaturized co-culture coupled to high-content screening. 2021 , 27, 128.e1-128.e7	5
231	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14
230	The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. 2021 , 72, e901-e913	19
229	Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. 2021 , 21, 36-43	6
228	Hydroxychloroquine/chloroquine and azithromycin in COVID-19 patients: prospective study of electrical parameters. 2021 , 56, 66-68	1
227	Review on therapeutic targets for COVID-19: insights from cytokine storm. 2021 , 97, 391-398	11
226	Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. 2021 , 57, 106236	1
225	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
224	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14
223	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. 2021 , 54, e12953	8
222	Combining Antivirals and Immunomodulators to Fight COVID-19. 2021 , 42, 31-44	21
221	Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France. 2021 , 40, 361-371	18
220	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891	1

219	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. 2021 , 5, 137-150	21
218	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. 2021 , 34, e14662	15
217	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899	6
216	Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. 2021 , 29, 1-11	69
215	East-West differences in clinical manifestations of COVID-19 patients: A systematic literature review and meta-analysis. 2021 , 93, 2683-2693	16
214	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
213	Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. 2021 , 93, 1265-1275	8
212	Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19. 2021 , 190, 491-495	5
211	Personal protective equipment against COVID-19: Vital for surgeons, harmful for patients?. 2021 , 221, 772-774	2
210	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. 2021 , 59, 12-23	24
209	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
208	Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?. 2021 , 72, 1467-1474	109
207	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0
206	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. 2021 , 40, 1649-1657	1
205	Prolonged Viral Shedding in Patients with Mild to Moderate COVID-19 Disease: A Regional Perspective. 2021 , 14, 11786337211010428	2
204	Therapeutic options for COVID-19: a quick review. 2021 , 33, 67-84	4
203	Hydroxychloroquine: A review of its safety and efficacy in COVID-19. 2021 , 10, 1124-1133	1
202	Cardiovascular Health and Disease in the Context of COVID-19. 2021 , 12, 67-79	7

201	Machine Learning-Based Prediction of COVID-19 Severity and Progression to Critical Illness Using CT Imaging and Clinical Data. 2021 , 22, 1213-1224	7
200	Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing. 2021 , 13, 7	8
199	COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home. 2021 , 255, 61-69	0
198	Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India. 2021 , 12, 58-59	3
197	Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. 2021 , 21, 58	24
196	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. 2021 , 32, 3-17	3
195	Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. 2021 , 153, 151-158	4
194	Cardiovascular safety of hydroxychloroquine: Brief appraisal of data. 2021 , 12, 224	
193	Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and meta-analysis. 2021 , 30,	0
192	The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. 2021 , 104, 35-38	13
191	Principles of Pharmacological Therapy. 2021 , 155-169	
190	COVID-19 in Qatar: Ways forward in public health and treatment. 2020 , 2020, 38	0
189	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. 2021 , 27, 694-707	1
188	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021 , 2, CD013587	57
187	From Diagnosis to Treatment: Recent Advances in Patient-Friendly Biosensors and Implantable Devices. 2021 , 15, 1960-2004	51
186	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
185	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. 2021 , 54, 37-45	2
184	Living with the virus: Infection and epidemiology of COVID-19 in hotspot area of India. 2021 , e2651	1

183	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. 2021 , 2021, 8821318	4
182	Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients. 2021 , 84, 233-241	17
181	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. 2021 , 12, 574425	13
180	Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. 2021 , 35, 4258-4283	11
179	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. 2021 , 35, 101658	2
178	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. 2021 , 397, 1063-1074	105
177	COVID-19, hydroxychloroquine and the importance of disease progression. 2021 , 10, 299-311	1
176	Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19.. 2021 , 14, 102983	6
175	COVID-19: Potential Repurposing Drugs. 2021 ,	2
174	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). 2021 , 45, 104-121	1
173	Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). 2021 ,	24
172	4-Aminoquinoline compounds from the Spanish flu to COVID-19. 2021 , 135, 111138	3
171	Comorbidities and Age Are Associated With Persistent COVID-19 PCR Positivity. 2021 , 11, 650753	3
170	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706	13
169	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. 2021 , 19, 1331-1339	2
168	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. 2021 , 22,	10
167	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. 2021 , 897190021997399	1
166	Antibiotic use in patients with Coronavirus disease 2019 (COVID-19): outcomes and associated factors. 2021 , 1-9	1

165	Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. 2021 , 4, 66		8
164	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. 2021 , 13,		12
163	Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: Comparison with RT-qPCR. <i>International Journal of Infectious Diseases</i> , 2021 , 105, 7-14	10.5	27
162	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,		
161	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. 2021 , 51, 411-420		8
160	Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020. 2021 , 26,		4
159	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. 2021 , 53, 137-143		2
158	Repurposing of antibiotics for clinical management of COVID-19: a narrative review. 2021 , 20, 37		11
157	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. 2021 , 11,		4
156	Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. 2021 , 26,		7
155	SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. 2021 , 13,		2
154	Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2021 , 41, 102005	8.4	1
153	Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis. 2021 , 16, e0251262		1
152	Therapeutic Agents Against COVID-19 with Clinical Evidence. 2021 , 27, 1608-1617		1
151	Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. 2021 , 8, 645172		1
150	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. 2021 , 10,		7
149	Use of glucocorticoids and azithromycin in the therapy of COVID-19. 2021 , 73, 1513-1519		0
148	Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. 2021 , e2258		10

147	Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data. 2021 , 508, 30-46		8
146	COVID-19 Management at IHU Mditerran Infection: A One-Year Experience. 2021 , 10,		0
145	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. 2021 , 51, 912-920		9
144	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. 2021 , 10,		2
143	Toxicity of hydroxychloroquine, a potential treatment for COVID-19, on free-living marine nematodes. 2021 , 167, 112361		5
142	Comparison of Roche and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021 , 108, 263-269	10.5	8
141	Investigating the Spread of Coronavirus Disease via Edge-AI and Air Pollution Correlation. 2021 , 21, 1-10		4
140	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. 2021 , 96, 107636		6
139	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. 2021 , 76, 285-295		3
138	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. 2021 , 19, 1219-1244		3
137	Knowledge, Attitude, and Practice Regarding COVID-19 Among Healthcare Workers in Primary Healthcare Centers in Dubai: A Cross-Sectional Survey, 2020. 2021 , 9, 617679		4
136	Mcanismes possiblement impliqu dans les effets antiviraux de la chloroquine et de lhydroxychloroquine Quelle rilit pour le traitement de la COVID-19 ?. 2021 , 33, 237-237		
135	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. 2021 , 1, 263-275		0
134	Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. 2021 , 58, 106428		2
133	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. 2021 , 905, 174191		8
132	Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. <i>Journal of the American Heart Association</i> , 2021 , 10, e021154	6	4
131	Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A. 2021 , 102,		0
130	Heterocyclic compounds as antiviral drugs: Synthesis, structureActivity relationship and traditional applications.		1

129	COVID-19: potential therapeutics for pediatric patients. 2021 , 73, 1520-1538		6
128	Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins. 2021 , 1238, 130457		4
127	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. <i>Journal of Clinical Epidemiology</i> , 2021 , 136, 55-63	5.7	6
126	investigation of pro-arrhythmic effects of azithromycin on the human ventricle. 2021 , 27, 101043		
125	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <i>Travel Medicine and Infectious Disease</i> , 2021 , 43, 102135	8.4	4
124	Role of Nucleocapsid Protein Antigen Detection for Safe End of Isolation of SARS-CoV-2 Infected Patients with Long Persistence of Viral RNA in Respiratory Samples. 2021 , 10,		2
123	Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. 2021 , 27, 1373-1374		1
122	Duration of infectious virus shedding in patients with severe coronavirus disease 2019 who required mechanical ventilation. 2022 , 28, 19-23		1
121	Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. 2021 , 28, 59570-59593		5
120	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. 2021 , 13, eabd5524		12
119	Scoping insight on antiviral drugs against COVID-19.. 2021 , 14, 103385		0
118	Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. <i>Travel Medicine and Infectious Disease</i> , 2021 , 44, 102163	8.4	2
117	COVID-19, cytokines, inflammation, and spices: How are they related?. 2021 , 284, 119201		15
116	What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review. 2021 , 38, 225		0
115	Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. 2021 , 33, 1718-1722		1
114	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. 2021 , 16, 281-308		21
113	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. 2021 , 21, 72		19
112	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. 2021 , 84, 22-34		6

111	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. 2021 , 379-416	7
110	Ophthalmic manifestations in the COVID-19 clinical spectrum. 2021 , 69, 691-694	4
109	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. 2020 , 14, 641-648	97
108	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. 2020 , 88, 106942	5
107	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. 2020 , 75, 363-370	20
106	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
105	Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France). 2020 , 18, 517-524	6
104	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. 2020 , 27, e573-e583	3
103	Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis.	5
102	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19.	5
101	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety: Systematic review of (hydroxy)chloroquine efficacy and safety.	1
100	Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France.	17
99	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.	82
98	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid.	5
97	Determining the period of communicability of SARS-CoV-2: A rapid review of the literature.	3
96	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study.	7
95	Genomic diversity and evolution of coronavirus (SARS-CoV-2) in France from 309 COVID-19-infected patients.	6
94	SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. 2020 , 21, e927304	4

93	Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression. 2020 , 8, 3669-3678	3
92	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. 2020 , 12, 604-611	6
91	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. 2020 , 20,	8
90	Severity of COVID-19 and diabetes mellitus: there is still a lot to be learned. 2020 , 64, 195-196	2
89	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
88	Diarrhoea in Patients with COVID-19. 2020 , 30, 51-56	5
87	COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. 2020 , 41, 517-526	26
86	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020 , 11, 597985	5.6 13
85	Should azithromycin be used to treat COVID-19? A rapid review. 2020 , 4,	21
84	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. 2020 , 52, 317-334	6
83	Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh. 2020 , 10, 27-30	7
82	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. 2020 , 11,	6
81	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. 2020 , 7, S110-S116	4
80	Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. 2021 , 14, 408-414	2
79	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. 2020 , 32, 166-196	22
78	Persistence of infectious SARS-CoV-2 particles for up to 37'days in patients with mild COVID-19. 2021 ,	3
77	Virtual Screening on Marine Natural Products for Discovering TMPRSS2 Inhibitors. 2021 , 9, 722633	0
76	Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.	

75	Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis.	0
74	SARS-CoV-2 infection and some controversies concerning therapy with chloroquine and hydroxychloroquine: case report and selected literature review. 2020 , 74, 348-353	
73	Meta-analysis. 2020 , 8, 73-87	
72	The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis. 2021 , 8, ofab533	6
71	First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France. 2021 ,	3
70	Cardiac Complications in Patients with COVID-19: An Integrative Literature Review. 2020 , 20, 1-13	1
69	Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. 2021 , 29, e88-e96	
68	Clarithromycin use for adjunct surgical prophylaxis before non-elective cesarean deliveries to adapt to azithromycin shortages in COVID-19 pandemic. 2020 , 15, e0244266	1
67	A Deep Language Model for Symptom Extraction from Clinical Text and Its Application to Extract COVID-19 symptoms from Social Media. 2021 , PP,	3
66	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. 2020 , 123, 74	
65	A comparative analysis of the COVID-19 pandemic response: The case of Turkey. 2020 , 7, 443-451	0
64	Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. 2020 , 24, S244-S253	0
63	A Multicenter Questionnaire-based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients. 2020 , 24, 919-925	0
62	Evaluation of patients treated by telemedicine in the COVID-19 pandemic by a private clinic in Sao Paulo, Brazil: A non-randomized clinical trial preliminary study.	
61	Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. 2021 , 15, 116-116	6
60	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.	1
59	Coronavirus and Homo Sapiens.	
58	Extinction of COVID-19 Clusters in a Lebanese Village: A Quick, Adapted Molecular and Contact tracing.	

57 ROMATOLOGIJ PERSPEKTIVIN DEN COVID-19.

56 Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2.

55 Update on COVID-19: A teleconference with the Paediatric Virology Study Group (Review). **2020**, 20, 293

54 Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. **2021**,

1

53 Treatment of SARS-CoV-2 (COVID-19): A safety perspective. **2021**, 10, 1-32

0

52 Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. *Therapeutics and Clinical Risk Management*, **2021**, 17, 1187-1198

2.9

0

51 Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19: Review. **2021**, 6, 100140

0

50 Covid-19: New Use of Therapeutics. **2021**, 299-313

49 Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. **2021**, 319, 01035

48 Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination.. *Science of the Total Environment*, **2021**, 152691

10.2

7

47 Update on COVID-19: A teleconference with the Paediatric Virology Study Group (Review). **2020**, 20, 1-1

46 Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study. **2021**,

1

45 High-cited favorable studies for COVID-19 treatments ineffective in large trials.

44 Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS-CoV-2 main protease and 3C-like protease for COVID-19 treatment.. *Clinical Nutrition Open Science*, **2022**,

3

43 Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.. *American Journal of Hypertension*, **2022**, 35, 462-469

2.3

1

42 An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.. *Brazilian Journal of Medical and Biological Research*, **2021**, 55, e11631

2.8

1

41 Treatment Options in CoViD19. **2022**, 63-94

40 Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment.. *Science of the Total Environment*, **2022**, 824, 153756

10.2

1

39	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021 , 23, 28	3.9	2
38	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review.. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022 , 7, e5-e23	9.9	0
37	Duration of viable SARS-CoV-2 shedding from respiratory tract in different human hosts and its impact on isolation discontinuation policies revision; a narrative review.. <i>Clinical Infection in Practice</i> , 2022 , 13, 100140	1	1
36	Optimizing peptide inhibitors of SARS-Cov-2 nsp10/nsp16 methyltransferase predicted through molecular simulation and machine learning.. <i>Informatics in Medicine Unlocked</i> , 2022 , 29, 100886	5.3	0
35	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. <i>Pathogens</i> , 2022 , 11,	4.5	4
34	Importance of gut microbiome regulation for the prevention and recovery process after SARS-CoV-2 respiratory viral infection (Review).. <i>Biomedical Reports</i> , 2022 , 16, 25	1.8	0
33	Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 844818	5.6	4
32	Value and prognostic impact of a deep learning segmentation model of COVID-19 lung lesions on low-dose chest CT. 2022 , 1, 100003		0
31	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time.. <i>Pathogens</i> , 2022 , 11,	4.5	2
30	Efficacy of tocilizumab in severe COVID-19: a retrospective study. <i>Journal of Health Sciences and Medicine</i> , 2022 , 5, 592-599	0	0
29	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <i>Journal of Clinical Epidemiology</i> , 2022 ,	5.7	1
28	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.. <i>Antibiotics</i> , 2022 , 11,	4.9	0
27	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <i>International Journal of Infectious Diseases</i> , 2022 ,	10.5	0
26	Follow-up of practiced treatment regimens and health conditions of patients following recovery from COVID-19 residing in Dhaka City: a survey-based, descriptive, cross-sectional study. <i>IJID Regions</i> , 2022 , 3, 68-75		0
25	SARS-CoV-2 Clinical Characteristics and Viral Shedding in Kuwait. <i>Medical Principles and Practice</i> , 2021 ,	2.1	
24	Treatment of COVID-19 disease in pregnancy and breastfeeding. <i>Sežnovskij Vestnik</i> , 2021 , 12, 44-54	0.3	
23	Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. <i>World Journal of Experimental Medicine</i> , 2022 , 12, 44-52	0.4	0
22	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1

21	Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. <i>Journal of the American Heart Association</i> ,	6	1
20	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 603-617	2.9	0
19	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. 2022 , 21-63		
18	Features of the intestine conditions at patients with a new coronavirus infection. 2022 , 94, 920-926		
17	Relevance of COVID-19 vaccine on the tourism industry: Evidence from China. 2022 , 17, e0269200		1
16	Contribution of Computed Tomography in the Diagnosis of Pulmonary Lesions Due to Coronavirus Disease (SRAS-CoV-2), COVID-19. 2022 , 12, 68-77		0
15	Influenza and coronavirus zoonoses: an overview on pandemic events, viral genome, replication and emergency preparedness. 2022 , 2, 1-11		0
14	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. 2022 , 12, 1456		0
13	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.		0
12	Molecular insight of phytochemicals from Indian spices and its hyaluronic acid conjugates to block SARS-CoV-2 viral entry. 1-20		0
11	Citation Misuses in the Biomedical Literature and Its Effects on Public Health. 2022 , 417-426		0
10	A Review of Potential Therapeutic Strategies for COVID-19. 2022 , 14, 2346		1
9	Prevalence and characteristics of antibiotic prescription for acute COVID-19 patients in Japan. 2022 , 12,		0
8	Repurposing of Chemotherapeutics to Combat COVID-19. 2022 , 22, 2660-2694		1
7	The Myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19 is far from reality. 2023 , 13,		0
6	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,		0
5	The Mouth-COVID-19 Connection: The Importance of the Oral Cavity for the Coronavirus Disease Part II. 2022 , 50, 175-181		0
4	A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available. 2023 , 21,		0

- 3 Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). **2023**, 13, 4471 ○
- 2 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 1 Hydroxychloroquine induces long QT syndrome by blocking hERG channel. **2023**, 3, 105-113 ○